Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies
Thomsen RW, Mailhac A, Løhde JB, Pottegård A
Diabetes Obes Metab. Pub. online 8 Apr 2025.
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Effect of marked weight loss on adipose tissue biology in people with obesity and type 2 diabetes
Samovski D, Smith GI, Palacios H, et al.
Diabetes Care. 2025:dc242739.
Leggi
Comparative efficacy and tolerability of currently approved incretin mimetics: a systematic analysis of placebo-controlled clinical trials
Kang YM, Punov V, Lim S, Nauck MA
Diabetes Obes Metab. Pub. online 11 Apr 2025.
Leggi
Latres E, Plum-Moerschel L, Murugesan SMN, et al. Diabetes Obes Metab. Pub. online 10 Apr 2025.
O’Hara DV, Jardine MJ
Diabetes Obes Metab. Pub. online 8 Apr 2025.
Leggi
An open-label, multiple ascending dose trial of orally administered insulin Tregopil in patients with type 1 diabetes mellitus to evaluate its pharmacokinetics, pharmacodynamics, safety and tolerability
Latres E, Plum-Moerschel L, Murugesan SMN, et al.
Diabetes Obes Metab. Pub. online 10 Apr 2025.
Leggi
Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
Böhm M, Butler J, Coats A, et al.
Eur Heart J. 2025;46(14):1304-1317.
Leggi
A comparative analysis of glycemic metrics derived from three continuous glucose monitoring systems
Freckmann G, Wehrstedt S, Eichenlaub M, et al.
Diabetes Care. 2025:dc250129.
Leggi
Oral semaglutide and cardiovascular outcomes in persons with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial
Marx N, Deanfield JE, Mann JFE, et al.
Circulation. Pub. online 29 Mar 2025.
Leggi
Parent-of-origin effects in the life-course evolution of cardiometabolic traits
Wagh R, Hatem G, Andersson J, et al.
Diabetologia. Pub. online 2 Apr 2025.
Leggi
Comparison of dose escalation versus switching to tirzepatide among people with type 2 diabetes inadequately controlled on lower doses of dulaglutide : a randomized clinical trial
Billings LK, Winne L, Sharma P, et al.
Ann Intern Med. Pub. online 2 Apr 2025.
Leggi